Trial intelligence / Profile preview

SELECT-D

2012-005589-37Phase 3Completed

Sponsor: University of Warwick
Start: Feb 2013
Modality: Recombinant Proteins and Enzymes, Small Molecules
Countries: 1

Overview

Phase 3, randomised, open-label trial in venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE) and 1 more comparing Rivaroxaban with Dalteparin sodium (2 arms). Started Feb 2013; status: completed.

Drugs

rivaroxabandalteparin

Conditions

venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)cancer

Beyond the preview

Go deeper on 2012-005589-37.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-005589-37.